Related Experiment Videos
In vitro activity of YTR 830
M R Jacobs1, S C Aronoff, P C Appelbaum
1Case Western Reserve University School of Medicine, Cleveland, OH 44106.
Journal of Chemotherapy (Florence, Italy)
|June 1, 1989
Summary
Tazobactam (YTR 830), a novel beta-lactamase inhibitor, shows potent in vitro activity against various bacteria, comparable to clavulanate and superior to sulbactam when combined with penicillins.
Area of Science:
- Microbiology
- Pharmacology
- Infectious Diseases
Background:
- Beta-lactamase enzymes confer resistance to beta-lactam antibiotics.
- Development of beta-lactamase inhibitors is crucial for overcoming antibiotic resistance.
Purpose of the Study:
- To evaluate the in vitro activity of tazobactam (YTR 830), a new penicillanic acid sulfone beta-lactamase inhibitor.
- To compare the efficacy of tazobactam with clavulanate and sulbactam when combined with penicillins.
Main Methods:
- In vitro susceptibility testing of tazobactam, clavulanate, and sulbactam in combination with penicillins.
- Evaluation against a panel of beta-lactamase producing bacterial strains, including Staphylococcus aureus, Haemophilus influenzae, Klebsiella, Escherichia coli, and anaerobes.
Main Results:
- Tazobactam, clavulanate, and sulbactam demonstrated activity against beta-lactamase producing strains of S. aureus, H. influenzae, Klebsiella, C. diversus, and most anaerobes.
- Tazobactam showed effectiveness against E. coli and indole-positive Proteus.
- The activity of tazobactam was comparable to clavulanate and superior to sulbactam.
Conclusions:
- Tazobactam is a potent beta-lactamase inhibitor with broad in vitro activity.
- Tazobactam represents a promising therapeutic option for infections caused by beta-lactamase producing bacteria.